Review



rofl 15141  (Cayman Chemical)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cayman Chemical rofl 15141
    <t>Rofl</t> <t>induces</t> <t>GRα</t> expression in COPD HBE cells. ( A-B ) COPD HBE cells were treated with the indicated concentrations of Rofl for 6 h ( A ) or with 1 µM of Rofl for the indicated periods ( B ) and GRα levels determined by Western blotting in whole-cell extracts and quantified by densitometric analysis. β-Actin served as a loading control. ( C ) Time course of transcriptional response to Rofl. After COPD HBE cells were treated with 1 µM Rofl or Veh control for 6 h, nascent mRNA captured by Click-iT Nascent RNA Capture Kit. Relative mRNA levels of GRα were measured by real-time PCR. ( D ) Effects of Rofl vs. Veh control on GRα mRNA stability in COPD HBE cells were determined by incubation in growth medium containing 5-EU followed by incubation in growth medium without 5-EU for the indicated periods. After total mRNA isolation, labeled mRNA was captured and analyzed with Click-iT Nascent RNA Capture Kit. Data are expressed as means ± SD; n = 3. ** P < 0.01, *** P < 0.001. Abbreviations: GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; n.s., non-significant; Rofl, roflumilast; Veh, vehicle.
    Rofl 15141, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rofl 15141/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    rofl 15141 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD"

    Article Title: Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD

    Journal: International Journal of Chronic Obstructive Pulmonary Disease

    doi: 10.2147/COPD.S230188

    Rofl induces GRα expression in COPD HBE cells. ( A-B ) COPD HBE cells were treated with the indicated concentrations of Rofl for 6 h ( A ) or with 1 µM of Rofl for the indicated periods ( B ) and GRα levels determined by Western blotting in whole-cell extracts and quantified by densitometric analysis. β-Actin served as a loading control. ( C ) Time course of transcriptional response to Rofl. After COPD HBE cells were treated with 1 µM Rofl or Veh control for 6 h, nascent mRNA captured by Click-iT Nascent RNA Capture Kit. Relative mRNA levels of GRα were measured by real-time PCR. ( D ) Effects of Rofl vs. Veh control on GRα mRNA stability in COPD HBE cells were determined by incubation in growth medium containing 5-EU followed by incubation in growth medium without 5-EU for the indicated periods. After total mRNA isolation, labeled mRNA was captured and analyzed with Click-iT Nascent RNA Capture Kit. Data are expressed as means ± SD; n = 3. ** P < 0.01, *** P < 0.001. Abbreviations: GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; n.s., non-significant; Rofl, roflumilast; Veh, vehicle.
    Figure Legend Snippet: Rofl induces GRα expression in COPD HBE cells. ( A-B ) COPD HBE cells were treated with the indicated concentrations of Rofl for 6 h ( A ) or with 1 µM of Rofl for the indicated periods ( B ) and GRα levels determined by Western blotting in whole-cell extracts and quantified by densitometric analysis. β-Actin served as a loading control. ( C ) Time course of transcriptional response to Rofl. After COPD HBE cells were treated with 1 µM Rofl or Veh control for 6 h, nascent mRNA captured by Click-iT Nascent RNA Capture Kit. Relative mRNA levels of GRα were measured by real-time PCR. ( D ) Effects of Rofl vs. Veh control on GRα mRNA stability in COPD HBE cells were determined by incubation in growth medium containing 5-EU followed by incubation in growth medium without 5-EU for the indicated periods. After total mRNA isolation, labeled mRNA was captured and analyzed with Click-iT Nascent RNA Capture Kit. Data are expressed as means ± SD; n = 3. ** P < 0.01, *** P < 0.001. Abbreviations: GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; n.s., non-significant; Rofl, roflumilast; Veh, vehicle.

    Techniques Used: Expressing, Western Blot, Control, Real-time Polymerase Chain Reaction, Incubation, Isolation, Labeling

    Rofl stimulates GRα promoter activity and induces GRα transcriptional activity. ( A ) Promoter activity. COPD HBE cells were treated with Rofl (0.5 or 1 µM) or Veh for 6 h, and then nuclear extracts were obtained and incubated with the indicated biotinylated double-stranded oligonucleotides corresponding to the following: WT or Mu GRα-CRE, the consensus CRE (positive control), or a nonspecific sequence (negative control). Bead-bound oligonucleotide-protein complexes were eluted and subjected to Western blotting to identify the presence of CREB. Western blotting for Lamin B1 was used as a control for non-specific interaction. Nuclear extracts without added nucleotides were loaded as input. ( B ) Transcriptional activity. GRα reporter cells were treated with the indicated concentrations (0–3 nM) of Rofl, Dex, or a combination of both for 24 h. GRα transcriptional activity, shown as the percent maximal response, was then measured using a GRα-specific reporter assay. Concentration-response curve fitting was performed by non-linear regression. Results were reproduced independently at least twice. Data are expressed as means ± SD; n = 3, *** P < 0.001. Abbreviations: CRE, cAMP response element; CREB, cAMP response element binding protein; Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; Mu, mutated; Rofl, roflumilast; Veh, vehicle; WT, wildtype.
    Figure Legend Snippet: Rofl stimulates GRα promoter activity and induces GRα transcriptional activity. ( A ) Promoter activity. COPD HBE cells were treated with Rofl (0.5 or 1 µM) or Veh for 6 h, and then nuclear extracts were obtained and incubated with the indicated biotinylated double-stranded oligonucleotides corresponding to the following: WT or Mu GRα-CRE, the consensus CRE (positive control), or a nonspecific sequence (negative control). Bead-bound oligonucleotide-protein complexes were eluted and subjected to Western blotting to identify the presence of CREB. Western blotting for Lamin B1 was used as a control for non-specific interaction. Nuclear extracts without added nucleotides were loaded as input. ( B ) Transcriptional activity. GRα reporter cells were treated with the indicated concentrations (0–3 nM) of Rofl, Dex, or a combination of both for 24 h. GRα transcriptional activity, shown as the percent maximal response, was then measured using a GRα-specific reporter assay. Concentration-response curve fitting was performed by non-linear regression. Results were reproduced independently at least twice. Data are expressed as means ± SD; n = 3, *** P < 0.001. Abbreviations: CRE, cAMP response element; CREB, cAMP response element binding protein; Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; Mu, mutated; Rofl, roflumilast; Veh, vehicle; WT, wildtype.

    Techniques Used: Activity Assay, Incubation, Positive Control, Sequencing, Negative Control, Western Blot, Control, Reporter Assay, Concentration Assay, Binding Assay

    Rofl inhibits IL-8 and TNFα production in COPD HBE cells additively with Dex in a GRα-dependent manner. ( A-B ) COPD HBE cells were treated with Rofl, Dex, or combined Rofl and Dex at indicated concentrations for 6 h. Culture medium was then collected, and IL-8 ( A ) and TNFα ( B ) levels in medium were determined by ELISA. Inhibitory effects of treatments are shown as fractional response. Curves were fitted by non-linear regression and the Bliss independence model. ( C-D ) COPD HBE cells received 24 h-transfection with scrambled or GRα siRNA and then were treated with Veh or combined Rofl and Dex (1 µM each) for 6 h. IL-8 ( C ) and TNFα ( D ) levels in culture medium were determined by ELISA. Data are expressed as means ± SD; n = 3. * P < 0.05, *** P < 0.001. ( E ) GRα expression in siRNA-transfected COPD HBE cells was determined by Western blotting and quantified by densitometric analysis. β-Actin served as a loading control. ** P < 0.01. Abbreviations: Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; IL-8, interleukin 8; n.s., non-significant; Rofl, roflumilast; TNFα, tumor necrosis factor alpha.
    Figure Legend Snippet: Rofl inhibits IL-8 and TNFα production in COPD HBE cells additively with Dex in a GRα-dependent manner. ( A-B ) COPD HBE cells were treated with Rofl, Dex, or combined Rofl and Dex at indicated concentrations for 6 h. Culture medium was then collected, and IL-8 ( A ) and TNFα ( B ) levels in medium were determined by ELISA. Inhibitory effects of treatments are shown as fractional response. Curves were fitted by non-linear regression and the Bliss independence model. ( C-D ) COPD HBE cells received 24 h-transfection with scrambled or GRα siRNA and then were treated with Veh or combined Rofl and Dex (1 µM each) for 6 h. IL-8 ( C ) and TNFα ( D ) levels in culture medium were determined by ELISA. Data are expressed as means ± SD; n = 3. * P < 0.05, *** P < 0.001. ( E ) GRα expression in siRNA-transfected COPD HBE cells was determined by Western blotting and quantified by densitometric analysis. β-Actin served as a loading control. ** P < 0.01. Abbreviations: Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; IL-8, interleukin 8; n.s., non-significant; Rofl, roflumilast; TNFα, tumor necrosis factor alpha.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Transfection, Expressing, Western Blot, Control



    Similar Products

    rofl 15141  (Cayman Chemical)
    90
    Cayman Chemical rofl 15141
    <t>Rofl</t> <t>induces</t> <t>GRα</t> expression in COPD HBE cells. ( A-B ) COPD HBE cells were treated with the indicated concentrations of Rofl for 6 h ( A ) or with 1 µM of Rofl for the indicated periods ( B ) and GRα levels determined by Western blotting in whole-cell extracts and quantified by densitometric analysis. β-Actin served as a loading control. ( C ) Time course of transcriptional response to Rofl. After COPD HBE cells were treated with 1 µM Rofl or Veh control for 6 h, nascent mRNA captured by Click-iT Nascent RNA Capture Kit. Relative mRNA levels of GRα were measured by real-time PCR. ( D ) Effects of Rofl vs. Veh control on GRα mRNA stability in COPD HBE cells were determined by incubation in growth medium containing 5-EU followed by incubation in growth medium without 5-EU for the indicated periods. After total mRNA isolation, labeled mRNA was captured and analyzed with Click-iT Nascent RNA Capture Kit. Data are expressed as means ± SD; n = 3. ** P < 0.01, *** P < 0.001. Abbreviations: GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; n.s., non-significant; Rofl, roflumilast; Veh, vehicle.
    Rofl 15141, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rofl 15141/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    rofl 15141 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Rofl induces GRα expression in COPD HBE cells. ( A-B ) COPD HBE cells were treated with the indicated concentrations of Rofl for 6 h ( A ) or with 1 µM of Rofl for the indicated periods ( B ) and GRα levels determined by Western blotting in whole-cell extracts and quantified by densitometric analysis. β-Actin served as a loading control. ( C ) Time course of transcriptional response to Rofl. After COPD HBE cells were treated with 1 µM Rofl or Veh control for 6 h, nascent mRNA captured by Click-iT Nascent RNA Capture Kit. Relative mRNA levels of GRα were measured by real-time PCR. ( D ) Effects of Rofl vs. Veh control on GRα mRNA stability in COPD HBE cells were determined by incubation in growth medium containing 5-EU followed by incubation in growth medium without 5-EU for the indicated periods. After total mRNA isolation, labeled mRNA was captured and analyzed with Click-iT Nascent RNA Capture Kit. Data are expressed as means ± SD; n = 3. ** P < 0.01, *** P < 0.001. Abbreviations: GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; n.s., non-significant; Rofl, roflumilast; Veh, vehicle.

    Journal: International Journal of Chronic Obstructive Pulmonary Disease

    Article Title: Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD

    doi: 10.2147/COPD.S230188

    Figure Lengend Snippet: Rofl induces GRα expression in COPD HBE cells. ( A-B ) COPD HBE cells were treated with the indicated concentrations of Rofl for 6 h ( A ) or with 1 µM of Rofl for the indicated periods ( B ) and GRα levels determined by Western blotting in whole-cell extracts and quantified by densitometric analysis. β-Actin served as a loading control. ( C ) Time course of transcriptional response to Rofl. After COPD HBE cells were treated with 1 µM Rofl or Veh control for 6 h, nascent mRNA captured by Click-iT Nascent RNA Capture Kit. Relative mRNA levels of GRα were measured by real-time PCR. ( D ) Effects of Rofl vs. Veh control on GRα mRNA stability in COPD HBE cells were determined by incubation in growth medium containing 5-EU followed by incubation in growth medium without 5-EU for the indicated periods. After total mRNA isolation, labeled mRNA was captured and analyzed with Click-iT Nascent RNA Capture Kit. Data are expressed as means ± SD; n = 3. ** P < 0.01, *** P < 0.001. Abbreviations: GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; n.s., non-significant; Rofl, roflumilast; Veh, vehicle.

    Article Snippet: Treatment with Dex (D4902; Sigma-Aldrich, St. Louis, MO, USA) and Rofl (15141; Cayman Chemical, Ann Arbor, MI, USA), GRα siRNA (SC35505; Santa Cruz Biotechnology, Santa Cruz, CA, USA) transfection, ELISA-based cytokine and chemokine measurement (DTA00D [TNFα] and D8000C [interleukin 8; IL-8]; R&D Systems, Minneapolis, MN, USA), and ELISA-based transcription factor-DNA binding assay (40096 [NFκB p65] and 45496 [GRα]; Active Motif, Carlsbad, CA, USA) have been described previously.

    Techniques: Expressing, Western Blot, Control, Real-time Polymerase Chain Reaction, Incubation, Isolation, Labeling

    Rofl stimulates GRα promoter activity and induces GRα transcriptional activity. ( A ) Promoter activity. COPD HBE cells were treated with Rofl (0.5 or 1 µM) or Veh for 6 h, and then nuclear extracts were obtained and incubated with the indicated biotinylated double-stranded oligonucleotides corresponding to the following: WT or Mu GRα-CRE, the consensus CRE (positive control), or a nonspecific sequence (negative control). Bead-bound oligonucleotide-protein complexes were eluted and subjected to Western blotting to identify the presence of CREB. Western blotting for Lamin B1 was used as a control for non-specific interaction. Nuclear extracts without added nucleotides were loaded as input. ( B ) Transcriptional activity. GRα reporter cells were treated with the indicated concentrations (0–3 nM) of Rofl, Dex, or a combination of both for 24 h. GRα transcriptional activity, shown as the percent maximal response, was then measured using a GRα-specific reporter assay. Concentration-response curve fitting was performed by non-linear regression. Results were reproduced independently at least twice. Data are expressed as means ± SD; n = 3, *** P < 0.001. Abbreviations: CRE, cAMP response element; CREB, cAMP response element binding protein; Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; Mu, mutated; Rofl, roflumilast; Veh, vehicle; WT, wildtype.

    Journal: International Journal of Chronic Obstructive Pulmonary Disease

    Article Title: Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD

    doi: 10.2147/COPD.S230188

    Figure Lengend Snippet: Rofl stimulates GRα promoter activity and induces GRα transcriptional activity. ( A ) Promoter activity. COPD HBE cells were treated with Rofl (0.5 or 1 µM) or Veh for 6 h, and then nuclear extracts were obtained and incubated with the indicated biotinylated double-stranded oligonucleotides corresponding to the following: WT or Mu GRα-CRE, the consensus CRE (positive control), or a nonspecific sequence (negative control). Bead-bound oligonucleotide-protein complexes were eluted and subjected to Western blotting to identify the presence of CREB. Western blotting for Lamin B1 was used as a control for non-specific interaction. Nuclear extracts without added nucleotides were loaded as input. ( B ) Transcriptional activity. GRα reporter cells were treated with the indicated concentrations (0–3 nM) of Rofl, Dex, or a combination of both for 24 h. GRα transcriptional activity, shown as the percent maximal response, was then measured using a GRα-specific reporter assay. Concentration-response curve fitting was performed by non-linear regression. Results were reproduced independently at least twice. Data are expressed as means ± SD; n = 3, *** P < 0.001. Abbreviations: CRE, cAMP response element; CREB, cAMP response element binding protein; Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; Mu, mutated; Rofl, roflumilast; Veh, vehicle; WT, wildtype.

    Article Snippet: Treatment with Dex (D4902; Sigma-Aldrich, St. Louis, MO, USA) and Rofl (15141; Cayman Chemical, Ann Arbor, MI, USA), GRα siRNA (SC35505; Santa Cruz Biotechnology, Santa Cruz, CA, USA) transfection, ELISA-based cytokine and chemokine measurement (DTA00D [TNFα] and D8000C [interleukin 8; IL-8]; R&D Systems, Minneapolis, MN, USA), and ELISA-based transcription factor-DNA binding assay (40096 [NFκB p65] and 45496 [GRα]; Active Motif, Carlsbad, CA, USA) have been described previously.

    Techniques: Activity Assay, Incubation, Positive Control, Sequencing, Negative Control, Western Blot, Control, Reporter Assay, Concentration Assay, Binding Assay

    Rofl inhibits IL-8 and TNFα production in COPD HBE cells additively with Dex in a GRα-dependent manner. ( A-B ) COPD HBE cells were treated with Rofl, Dex, or combined Rofl and Dex at indicated concentrations for 6 h. Culture medium was then collected, and IL-8 ( A ) and TNFα ( B ) levels in medium were determined by ELISA. Inhibitory effects of treatments are shown as fractional response. Curves were fitted by non-linear regression and the Bliss independence model. ( C-D ) COPD HBE cells received 24 h-transfection with scrambled or GRα siRNA and then were treated with Veh or combined Rofl and Dex (1 µM each) for 6 h. IL-8 ( C ) and TNFα ( D ) levels in culture medium were determined by ELISA. Data are expressed as means ± SD; n = 3. * P < 0.05, *** P < 0.001. ( E ) GRα expression in siRNA-transfected COPD HBE cells was determined by Western blotting and quantified by densitometric analysis. β-Actin served as a loading control. ** P < 0.01. Abbreviations: Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; IL-8, interleukin 8; n.s., non-significant; Rofl, roflumilast; TNFα, tumor necrosis factor alpha.

    Journal: International Journal of Chronic Obstructive Pulmonary Disease

    Article Title: Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD

    doi: 10.2147/COPD.S230188

    Figure Lengend Snippet: Rofl inhibits IL-8 and TNFα production in COPD HBE cells additively with Dex in a GRα-dependent manner. ( A-B ) COPD HBE cells were treated with Rofl, Dex, or combined Rofl and Dex at indicated concentrations for 6 h. Culture medium was then collected, and IL-8 ( A ) and TNFα ( B ) levels in medium were determined by ELISA. Inhibitory effects of treatments are shown as fractional response. Curves were fitted by non-linear regression and the Bliss independence model. ( C-D ) COPD HBE cells received 24 h-transfection with scrambled or GRα siRNA and then were treated with Veh or combined Rofl and Dex (1 µM each) for 6 h. IL-8 ( C ) and TNFα ( D ) levels in culture medium were determined by ELISA. Data are expressed as means ± SD; n = 3. * P < 0.05, *** P < 0.001. ( E ) GRα expression in siRNA-transfected COPD HBE cells was determined by Western blotting and quantified by densitometric analysis. β-Actin served as a loading control. ** P < 0.01. Abbreviations: Dex, dexamethasone; GRα, glucocorticoid receptor α; HBE, human bronchial epithelial; IL-8, interleukin 8; n.s., non-significant; Rofl, roflumilast; TNFα, tumor necrosis factor alpha.

    Article Snippet: Treatment with Dex (D4902; Sigma-Aldrich, St. Louis, MO, USA) and Rofl (15141; Cayman Chemical, Ann Arbor, MI, USA), GRα siRNA (SC35505; Santa Cruz Biotechnology, Santa Cruz, CA, USA) transfection, ELISA-based cytokine and chemokine measurement (DTA00D [TNFα] and D8000C [interleukin 8; IL-8]; R&D Systems, Minneapolis, MN, USA), and ELISA-based transcription factor-DNA binding assay (40096 [NFκB p65] and 45496 [GRα]; Active Motif, Carlsbad, CA, USA) have been described previously.

    Techniques: Enzyme-linked Immunosorbent Assay, Transfection, Expressing, Western Blot, Control